cover
Article Per Year (5 Year)
All
Home Page
OAI Link
Editorial Team
Contact
Reviewer
Google Scholar
Contact Name
Mustofa
Contact Email
mustofafk@ugm.ac.id
Phone
+6281328749273
Journal Mail Official
mustofafk@ugm.ac.id
Editorial Address
Department of Pharmacology and Therapy Radioputro Building 2nd Floor Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada Jl. Farmako Sekip Utara, Yogyakarta 55281 Indonesia
Location
Kab. sleman,
Daerah istimewa yogyakarta
INDONESIA
Indonesian Journal of Pharmacology and Therapy
Published by Universitas Gadjah Mada
ISSN : -     EISSN : 2745455X     DOI : https://doi.org/10.22146/ijpther.10147
Core Subject : Health, Science,
Immunology & microbiology Medicine & Pharmacology
Indonesian Journal of Pharmacology and Therapy (IJPTher ) is a scientific journal which published by Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada and Indonesian Pharmacologist Association or Ikatan Farmakologi Indonesia (IKAFARI). IJPTher is an open-access, and double-blind peer-reviewed journal published three Issues a year. IJPTher aims to communicate high-quality articles in the fields of pharmacology. IJPTher publishes original articles, review articles, case reports and book reviews in the fields of pharmacology including basic pharmacology, clinical pharmacology, pharmacotherapy, pharmacoepidemiology, pharmacogenetics, pharmacogenomics, pharmacoeconomic, toxicology and toxicogenomics.
Arjuna Subject : Pharmacology, Toxicology and Pharmaceutics - Pharmacology, Toxicology and Pharmaceutics (Lain-Lain)
Articles 5 Documents
 1 
Search results for , issue "Vol 4 No 3 (2023)" : 5 Documents clear
Prevalence and factors associated with uncontrolled blood pressure in dialysis patients using antihypertensive: a narrative review Pulungan, Yulianasari; Nugroho, Agung Endro; Pramantara, I Dewa Putu
Indonesian Journal of Pharmacology and Therapy Vol 4 No 3 (2023)
Publisher : Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada and Indonesian Pharmacologist Association or Ikatan Farmakologi Indonesia (IKAFARI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/ijpther.7768

Abstract

Hypertension in patients with end-stage chronic kidney disease undergoing hemodialysis is difficult to control leading to a significant risk factor for a cardiovascular event. The aimed of this review is to summarize the prevalence of uncontrolled blood pressure in dialysis patients. This review hopefully can serve as a valuable reference and source of insight for clinicians in their efforts to attain controlled blood pressure in dialysis patients. The relevant literatures was undertaken from PubMed, Scopus, and Google Scholar for studies addressing the factor associated with uncontrolled blood pressure in hemodialysis patients using antihypertensives from 2013 to 2023. Combinations of search terms were "uncontrolled" and "blood pressure" and "dialysis" and "antihypertensive”. Any study in English, including randomized control trials, cohort, case-control, and cross-sectional studies was included. Uncontrolled blood pressure is very common among hypertension in dialysis patients (28.7 - 78.33% of cases). Factors affecting blood pressure in dialysis patients include age, obesity, and comorbidity (diabetes and stage of chronic kidney disease). Although the relationship between gender, the number of antihypertensive, the number of dialysis, and the length of dialysis sessions with blood pressure varies, some studies have shown a positive association.
Improving hospital formulary drug decision making with multi-criteria decision analysis (MCDA): case study from a national government hospital in Indonesia Kristin, Erna; Bustami, Mursyid; Pinzon, Rizaldy Taslim; Alfi Yasmina; Susanto, Agnes; Febrinasari, Ratih Puspita
Indonesian Journal of Pharmacology and Therapy Vol 4 No 3 (2023)
Publisher : Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada and Indonesian Pharmacologist Association or Ikatan Farmakologi Indonesia (IKAFARI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/ijpther.7932

Abstract

This study aimed to look at the applicability of the multi-criteria decision analysis (MCDA) framework to improve hospital formulary drug decision-making. The case study method was used to investigate MCDA implementation in the National Brain Center Hospital Jakarta, Indonesia. A two stage-workshop was held on October 29th, 2019 and 5 February 5th, 2020, where participants conducted a hands-on experience in applying MCDA for selecting off-patent pharmaceuticals (OPPs) for the hospital formulary. The results of the workshop created awareness of MCDA that can be beneficial in transparently selecting OPP, which is not based only on price while involving multiple stakeholders. As a follow-up, MCDA was used during the drug selection process for the National Brain Center Hospital formulary in 2021 with criteria in accordance with the workshops, namely: 1) equivalence with the reference (originator) product; 2) real-world clinical or economic outcomes; 3) quality assurance; 4) reliability of drug supply; 5) stability and drug formulation; 6) pharmacovigilance, and 7) price advantages. In conclusion, the MCDA method can be implemented with customized criteria and weighting based on hospital needs to help with drug selection for the hospital formularies.
The role of angiotensin I - converting enzyme (ACE) insertion/deletion gene polymorphism in hypertension and ACE inhibitor therapy: a narrative review Handani, Dewa Ayu Sri; Zullies Ikawati; Hermawan, Adam
Indonesian Journal of Pharmacology and Therapy Vol 4 No 3 (2023)
Publisher : Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada and Indonesian Pharmacologist Association or Ikatan Farmakologi Indonesia (IKAFARI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/ijpther.8281

Abstract

Primary hypertension is the most prevalent type of hypertension, which is primarily attributed to genetic factors. The angiotensin-converting enzyme (ACE) gene has emerged as a prominent candidate among the genetic factors influencing blood pressure regulation. The ACE gene encodes the ACE, which plays a crucial role in the renin-angiotensin system. The ACE gene insertion/deletion (I/D) polymorphism is a variation of the ACE gene that affects blood pressure regulation. Individuals with II, ID, and DD genotypes may exhibit distinct ACE plasma concentrations, potentially contributing to variations in blood pressure levels and response to ACE inhibitor therapy. This article aimed to provide a comprehensive overview of the relationship between the ACE I/D gene with hypertension and angiotensin-converting enzym inhibitor (ACEI) effectiveness. This article presents a narrative review encompassing relevant studies published between 2013 and 2023. A systematic search was conducted using reputable databases such as PubMed, Science Direct, and Scopus. Inclusion criteria were applied, resulting in the selection of 25 articles that met the predefined criteria. The analysis included 25 studies, comprising 5 articles that investigated the impact of ACEI therapy and 20 articles that examined the ACE I/D gene polymorphism in hypertensive populations without ACEI therapy. It can be concluded that compared to the I allele, the D allele of the ACE I/D gene is associated with a higher level of essential hypertension and a reduced ACEI response.
Effectiveness of azithromycin and ciprofloxacin in the treatment of typhoid fever: a systematic review Mulyono, Bethea Manuela; Ita Margaretha Nainggolan; Linawati Hananta; Lucky Hartati Moehario
Indonesian Journal of Pharmacology and Therapy Vol 4 No 3 (2023)
Publisher : Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada and Indonesian Pharmacologist Association or Ikatan Farmakologi Indonesia (IKAFARI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/ijpther.8945

Abstract

Typhoid fever or commonly referred to as enteric fever is a systemic disease caused by Salmonella typhi. It often occurs in developing countries due to poor sanitation. Second-line antibiotics, including ciprofloxacin, have been widely used as the first choice treatment for typhoid fever. However, S. typhi has increased resistance to second-line antibiotics, so azithromycin has become an alternative treatment for the typhoid fever. This systematic review assessed the effectiveness of azithromycin and ciprofloxacin against typhoid fever in adults. This research used the PRISMA protocol with predefined Pubmed, Proquest, and EBSCO keywords. After removing duplicates and selecting studies according to inclusion and exclusion criterias, 17 studies about the effectiveness of azithromycin and ciprofloxacin in typhoid fever in adults from 1988-2020 were gathered. Studies were evaluated using JBI Critical Appraisal Tools. The results showed that administration of azithromycin and ciprofloxacin for typhoid fever yields average length of fever (3.5 d and 4.2 d) and average length of stay (9.3 d and 10 d), respectively. The susceptibility of S. typhi to azithromycin was 99.9%, whereas a significant decrease in its susceptibility to ciprofloxacin was observed in 2017-2020, from 4% to 2%. Azithromycin showed better effectiveness than ciprofloxacin in treating typhoid fever in adults based on S. typhi’s susceptibility, average length of fever and average length of stay from 17 studies reviewed.
Thyroid medications and patient adherence: understanding prescription patterns and factors influencing treatment compliance Poojary, Bhavya; Wilson, Merlin Maria; Jose, Riya; Sam, Sona P; George, Ann Elizabeth
Indonesian Journal of Pharmacology and Therapy Vol 4 No 3 (2023)
Publisher : Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada and Indonesian Pharmacologist Association or Ikatan Farmakologi Indonesia (IKAFARI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/ijpther.9375

Abstract

Thyroid problems are common in India affecting around 42 million people. Early diagnosis and therapy play an important role in managing this endocrine disorder. Hypothyroidism and hyperthyroidism are the most common thyroid disorders and are treated with thyroid hormone replacement therapy and antithyroid drugs. However, medication adherence, side effects, and misunderstanding of the importance of medication lead to inconsistent intake. This study aimed to evaluate the pattern of prescribing and adherence to thyroid medication. This cross-sectional study was conducted over 6 months in a tertiary care hospital, involving 188 patients with thyroid disorders. Data was collected using a validated form and medication adherence rationing scale. The collected data, including MARS scores, were entered into Microsoft Excel and analyzed using IBM SPSS Version 25. Quantitative data were analyzed using the mean and standard deviation, while categorical data were summarized using frequencies and percentages. The Chi-square test was used to evaluate associations, with a significance level of p < 0.05. In our study, 163 participants diagnosed with hypothyroidism exhibited a notable adherence rate of 89.57%. The 25 hyperthyroid patients showed strong adherence to the recommended drugs, with those provided methimazole having the highest adherence rate (52.0%). No statistically significant connections were found when examining the variables affecting drug adherence. Levothyroxine and methimazole were the preferred medications for managing hypothyroidism and hyperthyroidism, respectively. A high adherence rate among patients indicates heightened awareness and understanding of their condition, as well as consistent adherence to the medication schedule. These findings emphasize the importance of early diagnosis, appropriate prescription patterns, and patient adherence in effectively managing thyroid disorders.

Page 1 of 1 | Total Record : 5

 1 

Filter by Year

2023 2023


Reset
Filter By Issues
All Issue Vol 6 No 3 (2025) Vol 6 No 2 (2025) Vol 6 No 1 (2025) Vol 5 No 3 (2024) Vol 5 No 2 (2024) Vol 5 No 1 (2024) Vol 4 No 3 (2023) Vol 4 No 2 (2023) Vol 4 No 1 (2023) Vol 3 No 3 (2022) Vol 3 No 2 (2022) Vol 3 No 1 (2022) Vol 2 No 3 (2021): Special Issue: COVID-19 Vol 2 No 3 (2021) Vol 2 No 2 (2021) Vol 2 No 1 (2021) Vol 1 No 2 (2020) Vol 1 No 1 (2020) More Issue